Global Respiratory Disease Testing Market Size (2024 - 2029)

Respiratory Disease Testing Market Analysis

The Global Respiratory Disease Testing Market size is estimated at USD 5.80 billion in 2024, and is expected to reach USD 6.97 billion by 2029, growing at a CAGR of 3.77% during the forecast period (2024-2029).

The studied market was hampered due to strict lockdowns and regulations by the government authorities at the beginning of the COVID-19 pandemic. The supply chain was disrupted due to this. The lockdowns imposed were followed by the cancellation of medical visits and disease diagnoses. This resulted in delays in respiratory testing and diagnostic procedures. However, the incidence of COVID-19 among respiratory patients increased. This created a demand for testing during the pandemic. According to the research article published in December 2021 by Respiratory Medicine and Research, patients with chronic respiratory diseases (CRD) were likely to experience respiratory symptoms from viral respiratory infections, including the SARS-CoV-2 infection, which can worsen the condition and necessitate hospitalization. However, the stabilizing cases of COVID-19 are expected to stabilize the growth of the market in the coming years. As per the weekly update by WHO in November 2021, after a 5-week drop, global COVID-19 cases stabilized last week, though deaths continued to decline. Cases were down in all but one of the six world regions, with the biggest drop in African countries (-35%). Thus, the COVID-19 pandemic had a considerable impact on the market.

Factors such as the growing burden of respiratory diseases and technological advancements in testing devices and modalities are expected to fuel the market growth over the forecast period.

Respiratory symptoms are among the leading causes of consultation with doctors and physicians in primary healthcare centers. Some of the major preventable chronic respiratory disorders are asthma, COPD, allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). The data updated by the CDC in September 2022 mentioned that 873,000 emergency department visits with COPD were reported in 2020 in the United States, and 5% of adults were diagnosed with COPD, emphysema, or chronic bronchitis for the first time. Thus, it shows the burden of the disease on society is expected to increase the demand for respiratory disease testing, which is expected to boost the growth of the market.

In addition, development activities such as product launches, approvals, acquisitions, and mergers, among other activities, are driving the overall market growth. For instance, in November 2021, Cipla Limited launched Spirofy, India's first pneumotach-based portable, wireless Spirometer, on World COPD Day. With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis in India. Such developments are anticipated to contribute to the market growth over the forecast period.

Therefore, due to the factors mentioned above, the studied market is anticipated to witness growth during the forecast period. However, the stringent regulatory framework for product approval is predicted to hinder the market growth.

Respiratory Disease Testing Industry Segmentation

As per the scope of the report, respiratory disease testing is used for the diagnosis of respiratory conditions in an individual. Some respiratory diseases include chronic obstructive pulmonary disease, asthma, and infections such as bacterial pneumonia and enterovirus respiratory virus. The respiratory disease testing market is segmented by Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests), End-user (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.